Safety of fluoroquinolones and cotrimoxazole in urinary tract infections in older males

Clicks: 5
ID: 313913
2026
Free PDF
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This article has not been analysed, so there is no overall score — reader engagement is measured and shown alongside.
AI Quality Assessment
Not analyzed
Readership in this journal
Emerging

Ranked #105 of 214 articles by views in Open forum infectious diseases

Most read Least read

Bar heights use a square-root scale. Only the 120 most-read articles are drawn; the journal has 214 in total.

Mint this article as an NFT
Not yet minted

Create a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.

5 SUSD one-off · no wallet required
Sign in to mint
Abstract
Abstract Objectives Guidelines recommend fluoroquinolones or cotrimoxazole for urinary tract infections in men (UTIm), but safety data in frail older patients remain limited. The aim of this study was to compare the tolerability of these antibiotics in UTIm patients over 75 years. Participants and Methods This multicentre retrospective study included patients ≥75 years hospitalized for UTIm in 8 hospitals and treated with oral fluoroquinolone or cotrimoxazole. Adverse events (AEs) during hospitalization were compared. Results Among 228 patients included (median age 85), 131 (57.4%) received fluoroquinolones and 97 (42.6%) cotrimoxazole. Baseline characteristics were similar. AEs occurred 29.7% of fluoroquinolone-treated patients versus 48.5% with cotrimoxazole (p=0.006), leading to treatment discontinuation in 2.3% vs 11.3% (p=0.009). Acute kidney injury was observed in 7.2% vs 29.4% (p<0.001); metabolic disorders in 7.6% vs 18.6% (p=0.023). Other AEs and mortality did not differ significantly. Cotrimoxazole was associated with a doubled risk of AEs (adjusted OR 2.10 [1.18–3.74], p=0.01). Conclusions These results suggest a better safety profile of fluoroquinolones than cotrimoxazole in the treatment of UTI in older men. These results need to be confirmed in a prospective design.
Reference Key
openalex_W7160819682 Use this key to autocite in the manuscript while using SciMatic Manuscript Manager or Thesis Manager
Authors C Gouraud, A Putot, T Fraisse, M Bermejo, B Viala, C Golstein, N Lemarie, C Roubaud Baudron, P Caraux-Paz
Journal Open forum infectious diseases
Year 2026
DOI
10.1093/ofid/ofag271
URL
https://doi.org/10.1093/ofid/ofag271
Keywords Keywords not found

Citations

No citations found. To add a citation, contact the admin at info@scimatic.org

Comments

No comments yet. Be the first to comment on this article.